I. Introduction
Many patients with cancer of head and neck receive treatment with radiotherapy. Radiotherapy has expanded its role in functional organ preservation. Addition of concurrent chemotherapy has improved treatment outcome in these patients. The results of radiation treatment is totally dependent on treatment compliance, which is very challenging in our population. Treatment related toxicities are an important factor impairing treatment compliance, thereby effecting therapeutic outcome. Multiple studies have assessed the clinical impact of unplanned treatment gap. One study estimated a 50% loss of local control and overall survival when the treatment time exceeded planned duration by more than 14days [3] . Other groups have evaluated loss of local control with increased length of treatment time for various head and neck patients, with a calculated mean reduction in 5 years local control of 1.7% (range 0.4% to 2.9%) for each day that treatment is prolonged. [5] In this study, we document compliance rates, common reasons, why treatments are missed and evaluate whether demographic, tumor related and treatment related factors are correlated with treatment compliance in head and neck cancer patients from the institution.
II. Materials And Methods
The patients of head and neck malignancy treated with radiotherapy between July 2014 to December 2016 were included in this retrospective study. All records regarding primary malignancy, radiotherapy and chemotherapy were available for review.
Treatment Course:-All patients underwent a 5 to 7 weeks course of daily radiation treatment to the primary tumor site and regional lymph nodes. Patients underwent computed tomography simulation in a supine position with face mask immobilization. Radiation was delivered with intensity modulated radiation therapy (IMRT) or threedimensional conformal radiation therapy (3DCRT) . Concurrent chemotherapy was administered in cases that were medically indicated. Radiation dose ranged from 50gy to 70gy and were prescribed independently of intent to administer chemotherapy.
Treatment Compliance:-
Length of radiotherapy treatment course and number of radiotherapy treatment missed were recorded . Reasons for missed treatment were recorded in the patients file by us. For purpose of this study, treatment noncompliance was defined as prolongation of length of treatment by at least 7 calendar days beyond the length of planned treatment course. With a theoretical loss of local control of 1.7% per unplanned treatment day according to previously published data, this would incur an approximately 10% reduction in 5 year local control. [4] The demographic, tumor related and treatment related variables were recorded ; the total number of missed treatment ,age, gender, marital status, education, socio-economic status, baseline performance status according to ECOG scale, nutritional status , primary site of cancer, American joint committee on cancer ( AJCC) tumor stage, radiotherapy technique, concurrent chemotherapy and highest grade acute toxicity. To determine risk factors for non-compliance, the association between any missed treatment (yes or no ) and all categorical variables was assured using the chi square test. Estimated loss of local control was calculated using a projected 1.7 % radiation in control for each unplanned missed treatment day. [4] Public holidays observed at our institution were not counted as missed treatment days.
Measurment Of Acute Toxicity:-
During the radiotherapy treatment course, patients were evaluated weekly .The severity of acute toxicity symptoms, graded on a scale 1 through 5, according to common terminology criteria for adverse events version 3.0 were noted. These notes were reviewed and recorded.
III. Results
Patient & Tumour CharacteristicsSixty seven HNC patients were identified. The patients were in the age group of 20-76 years . there were 49 males and 18 females in the study group , 33 patients belonged to low socioeconomic group. The most common primary tumor sites were oral cavity (67%), Larynx (11%) and oropharynx (10%). Majority of the patients had advanced stage disease and the distribution of AJCC stage grouping was I=8 (11.9%), II=12 (17.9%), III=21(31.3%), IVA=19(28.4%), IVB=2(3%).10 patients (14.9%) received concurrent chemotherapy . 
Treatment Compliance-
Eight four percent of patient were compliant with the radiotherapy treatment course (defined as prolonging treatment by fewer than 7 calendar days). 24 patients (36%) completed radiotherapy with no missed treatment, 32 patients (48%) missed one to six treatment, 4 patients (6%) missed seven to fourteen treatment while 3 patients missed more than 14 treatments (4%), 3 patients did not complete the treatment (4%) while 1 patients did not start the ( 1.5% ) treatment.
The most common cause for missed treatment were hospitalization (25% of event ) and toxicity (20% of event ). The reasons for hospitalization were chemotherapy administration, blood transfusion and treatment related toxicity. Other reasons for missed treatment were lack of transportation due to local bandh (10%), patient refusal (10%), and treatment machine breakdown (10%). 2 % patients missed treatment due to some family emergency situation. 20 % of the patients missed treatment due to unknown reasons.
Toxicity
Grade ( CTCAE Version 3)* *Common Terminology Criteria for Adverse Events version 3.0* Numerous acute toxicities were observed. The most common grade 3 toxicity were mucositis, dermatitis and hematological toxicity. There were no grade 4 toxicity reported (Table No. 2).
IV. Discussion
Delays in radiotherapy treatment of head and neck carcinomas have resulted in inferior treatment outcome. Protraction of treatment time decreased the rate of loco regional control for head and neck cancer in several retrospective analyses, which is consistent with accelerated tumor regeneration. With conventional daily treatment schedule, using one fraction per day, these studies describe a loss of local control of 0.4% to 2.9% for each day the treatment course is prolonged, with an average of 1.7% day . Loss of local control is primarily attributed to tumour repopulation during a treatment gap. [9, 10] Several methods have been proposed to compensate for prolonged treatment time , including treatment on weekend days or treating two fractions in one day to retain both overall treatment time and dose per fraction, adding on missed fraction to the end of the treatment, to retain dose per fraction and total dose while accepting protraction, or increasing dose per fraction while maintaining treatment time. [4] However, each of these methods has drawbacks. Late effects might be enhanced by increasing the fraction size or treating two fractions in one day, if the inter fraction time is short. [2] Our department added the missed fraction to the end of the treatment course at same dose per fraction. Khalil and colleagues investigated treatment compliance in HNC patient participating in four randomized controlled trials through the European organization for Research and treatment of cancer, Princess Margaret hospital and a continuous hyper fractionated accelerated radiotherapy trial.(CHART) 25 % of patient in these trials had delays of 6 days or more.
Although many studies have assessed compliance rate, few have been able to identify specific predictors of non-compliance. Patel and colleagues, evaluated the predictive value of ethnicity, gender, primary tumor site, stage and nodal status, but did not find any significant variable that could predict for noncompliance. [5] Rajni A. Sethi and colleagues, evaluated several demographic, toxicity and treatment variables for reasons for missed treatment, they found patients with percutaneous endoscopic gastrostomy tube were more likely to missed treatment (P=.01). No other variable showed a significant association with missed treatments. [1] A larger study assessing 5086 head and neck cancer patients enrolled in Medicare, a federal health insurance plan in the United State, reported that 39% of the patients had prolonged or incomplete treatment. Patients who underwent surgery prior to radiotherapy were more likely to complete uninterrupted
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DOI: 10.9790/0853-1604074852 www.iosrjournals.org 51 | Page radiotherapy possibly, due to selection of healthier patients motivated to undergo more rigorous therapy with both surgery and radiation. [15] We evaluated multiple socio-economic, demographic, tumor related and treatment related variables as risk factor for non-compliance, but no variable was significant enough to predict non-compliance. The relatively small sample size and low number of missed treatments might have precluded finding other factors that predicted compliance. The most frequent reasons for each missed treatment were noted as reported by the patient, treating physician or radiation technologist at the time of patient absence. Missed treatments were most commonly caused by hospitalization, acute toxicity, treatment machine maintenance. As majority of our patients belonged to low socio-economic status , with poor educational background and were noted to be unaware about the importance of the ongoing treatment. Other reasons were patients refusal, local Bandh /strike. Therefore, there is need to increase awareness about the disease and its treatment to improve treatment outcome. Although prospective studies are required to evaluate risk factor for non-compliance in the population, it is also important for individual institutions to assess site specific weaknesses in health care delivery that impedes treatment compliance. 
V. Conclusion
Definitive radiotherapy for head and neck cancer can be delivered with good adherence in our patient population. Eighty four percent of our treated patients completed treatment with 0 to 6 days of treatment interruption. Further studies are required to evaluate the risk factors for non-compliance. Public awareness about the disease and treatment should be ensured to improve treatment compliance.
